Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2010

View Archived Issues

MerLion Pharmaceuticals claims new macrolides

Astellas reports last year's product highlights

GE Healthcare identifies novel contrast agents for X-ray-based diagnosis

Novel antiviral compounds disclosed by GlaxoSmithKline

ACADIA describes new muscarinic acetylcholine receptor agonists

Merck & Co. identifies novel PDE10A inhibitors

Promising data reported on house dust mite allergy therapies

Zolpidem improves limb dystonia

Pridopidine beneficial in patients with Huntington's disease

ExonHit and Genmab sign agreement on new potential breast cancer targets

AMRI completes acquisition of Hyaluron

MultiCell contracts CDSS to manage phase IIb MCT-125 trial

GPR17 antagonist ticagrelor shows preclinical promise to treat demyelinating conditions

Endocyte presents interim phase I data on FR-targeting conjugates in solid tumors

Idarubicin/busulphan improves outcome of autograft in patients with NPM1-mutant AML

SCH-900105 is safe and advances from phase I to phase II trial

Promega and CDI validate predictive stem cell-based cardiotoxicity assays

FoldRx achieves funds to market tafamidis meglumine

Anacor reports on phase IIb trial of AN-2728 in psoriasis

Galera to advance dismutase mimetics for prevention of oral mucositis

EC grants QPI-1002 orphan status for prevention of DGF

Biogen enrolls first patient in phase II combination trial of BG-12 in MS

Pieris begins phase I trial of anticalin PRS-050 in cancer

Inovio begins immunization in phase I trial of VGX-3400X universal flu vaccine

EMA approves update to bortezomib label for multiple myeloma

Tranzyme and Norgine to codevelop ulimorelin in Europe and other regions

Anacor's AN-3365 achieves proof of concept in collaboration with GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...